---
document_datetime: 2023-09-21 20:13:40
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ribavirin-mylan-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: ribavirin-mylan-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.181277
conversion_datetime: 2025-12-24 04:19:12.915222
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ribavirin Mylan

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on on 13/03/2019 product   | Commission Decision Issued 2 / amended Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------|-----------------------------------------------------------|-------------------------------------------------------------------------|-----------|
| N/0030               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) |                                                           | PL                                                                      |           |
| T/0029               | Transfer of Marketing Authorisation                                                              | 25/07/2018 03/08/2018                                     | SmPC, Labelling and PL                                                  |           |
| IAIN/0028/G          | This was an application for a group of variations.                                               | 31/05/2018 n/a                                            |                                                                         |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

Medicinal product no longer authori

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                    |            |                                                                                                                                                                                                                                                                                                                                                                           |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0024             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                     | 25/05/2016         | n/a        | authorised                                                                                                                                                                                                                                                                                                                                                                |
| IAIN/0023/G         | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF | 08/12/2015         | n/a no     | longer                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/10007 /201407 | Periodic Safety Update EU Single assessment - ribavirin (oral formulations)                                                                                                                                                                                                                                                                                                                                                                                              | 12/02/2015         | n/a        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                         |
| R/0021              | location Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                         | 18/12/2014 product | 11/02/2015 | Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP is of the opinion that the quality, safety and efficacy of Ribavirin Mylan continues to be adequately and sufficiently demonstrated and therefore considered that the benefit risk profile of Ribavirin Mylan continues to be favourable. |
| IAIN/0020/G         | This was an application for a group of variations. A.5.b - Administrative change - Change in the name Medicinal                                                                                                                                                                                                                                                                                                                                                          | 22/09/2014         | n/a        |                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information   |                          | longer          | authorised                                                                                                                                 |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0019             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                          | 21/08/2014 11/02/2015    | SmPC            |                                                                                                                                            |
| PSUSA/10007 /201307 | Periodic Safety Update EU Single assessment - ribavirin (oral formulations)                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 20/02/2014 28/04/2014 no | SmPC and PL     | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10007/201307. |
| IAIN/0016/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not 12/03/2014 Medicinal product                                         | 11/02/2015               | Annex II and PL |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|             | including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                                         |                                                                                                                                                                                                                                                                         |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0017     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                           | 11/03/2014 | 11/02/2015 | SmPC and PL                             | To update sections 4.1, 4.4, 4.8 and 5.1 of the SmPC with long-term follow-up safety data on the durability of virologic response and growth amongst paediatric patients from study P02538, section 4 of the PL is updated accordingly. authorised                      |
| IB/0014     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                         | 01/08/2013 | 18/12/2013 | SmPC, Annex II, Labelling and PL longer | To bring the annexes in line with the originator and to updated to the latest QRD version. In addition the MAH took this opportunity to update the details of the local representative in DK. The MAH also updated the annexes to include the new Member State Croatia. |
| IAIN/0013/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site Medicinal product | 12/04/2013 | n/a no     |                                         |                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes   |            |            | authorised             |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IB/0007   | C.I.8.b - Introduction of a new Pharmacovigilance system - which has been assessed by the relevant NCA/EMA for another product of the same MAH                                                                                                                                                  | 16/01/2012 | n/a        |                        |
| IA/0006/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non-sterile medicinal products             | 11/05/2011 | n/a no     | longer                 |
| N/0005    | The MAH took this opportunity to add the list of local representatives Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) product                                                                                                                 | 07/03/2011 | n/a        | PL                     |
| T/0004    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                             | 17/12/2010 | 27/01/2011 | SmPC, Labelling and PL |
| IA/0003   | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs Medicinal                                                                                                                                                                                       | 17/12/2010 | n/a        | SmPC, Labelling and    |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                |            |     | PL                 |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------|
| IB/0002 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH | 14/12/2010 | n/a | SmPC and PL        |
| IB/0001 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH | 14/12/2010 | n/a | SmPC and Labelling |

<!-- image -->